Skip to main content

Table 6 Univariate analysis of characteristics and osteosarcoma patient survival based on the log-rank test

From: Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma

Clinicopathologic data Case number Disease-free survival (months) Overall survival (months)
Mean SD 95%CI P value Mean SD 95%CI P value
Sex
 Male 38 53.81 5.59 42.85–64.76 NS 71.04 4.39 62.44–79.65 NS
 Female 22 32.39 5.13 22.34–42.44   53.81 6.59 40.91–66.72  
Age (years)
 < 18 26 37.42 5.43 26.79–48.06 NS 51.51 4.42 42.84–60.17 NS
 ≥ 18 34 51.96 5.91 40.37–63.54   68.56 5.00 58.75–78.36  
Tumor location
 Tibia or femur 40 49.67 5.56 38.77–60.57 NS 67.47 4.52 58.60–76.33 NS
 Other location 20 46.15 7.57 31.32–60.98   60.55 6.86 47.10–74.00  
Histologic subtype
 Conventional 55 49.20 4.77 39.86–58.54 NS 66.42 3.97 58.64–74.20 NS
 Special 5 40.20 10.96 18.71–61.69   55.40 14.72 26.54–84.26  
Tumor size (cm)
 < 5 23 65.17 6.63 52.18–78.17 0.006 77.91 4.36 69.38–86.45 0.015
 ≥ 5 37 36.39 4.97 26.65–46.12   55.98 4.96 46.26–65.71  
Enneking staging
 I-IIA 21 70.05 6.27 57.75–82.34 0.001 79.71 4.25 71.39–88.04 0.010
 IIB 39 36.42 5.08 26.46–46.38   56.54 4.87 47.00–66.07  
Response to chemotherapya
 Good 28 63.86 6.14 51.83–75.89 0.002 79.11 3.76 71.74–86.48 0.001
 Poor 32 32.84 4.91 23.22–42.47   51.56 5.42 40.94–62.18  
  1. SD standard deviation, CI confidence interval, NS no significance
  2. aGood: tumor necrosis ≥ 90%; poor: tumor necrosis < 90%